Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Argent Biopharma ( (AU:RGT) ) has shared an announcement.
Argent BioPharma has completed the acquisition of AusCann Group Holdings’ interest in CannPal Animal Therapeutics, securing a Phase 3 veterinary epilepsy program focused on seizure management in dogs and a defined path toward near-term commercialisation. The deal also delivers an option over the Neuvis oral drug delivery platform, a proprietary system designed to enhance bioavailability and formulation performance across multiple assets.
The CannPal data package, including advanced clinical and safety datasets, is expected to strengthen Argent’s neurological portfolio by bolstering the clinical and regulatory positioning of its lead epilepsy candidate CannEpil. Management says the transaction expands the company’s late-stage asset base with potential standalone veterinary revenues, reinforces its intellectual property profile, and supports its ambition to meet the scale and portfolio requirements of a future U.S. national exchange listing.
More about Argent Biopharma
Argent BioPharma Ltd is a revenue-generating, clinical-stage biopharmaceutical company focused on nano-engineered therapeutics for neurological and immune-mediated disorders. Its lead assets, CannEpil for drug-resistant epilepsy and CimetrA for inflammatory conditions, leverage proprietary nano-delivery technologies and vertically integrated EU-GMP manufacturing to target central nervous system and systemic inflammatory diseases with significant unmet need.
YTD Price Performance: -52.86%
Average Trading Volume: 193,999
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$3.67M
For a thorough assessment of RGT stock, go to TipRanks’ Stock Analysis page.